Welcome to aadibio.com

In pursuit of the exceptional responder – Aadi Bioscience, Inc. (ABI), is dedicated to finding the right therapy for the right patient at the right time.
AADi is developing a potentially best-in-class mTOR inhibitor for patients in whom the biology of the disease matches the selectivity of the drug.

For information on our registration study in Advanced Malignant PEComa latest PEC- 001 study, please visit our study page: http://www.mypecomastudy.com/the-pec-001-study/

For information on our Pulmonary Arterial Hypertension study, please visit our study page:

Note: This website is currently being updated.

Homepage – Layer Slider

March, 7 2019, Aadi Bioscience, Inc. (Aadi), For the first time in his life, Shanahan “Shanny” Dameral, 19, has a girlfriend. Soon, he’ll be graduating with a high school diploma and looking for his first job on the Kitsap Peninsula. What seems routine for many is a big deal for Dameral and other children living with treatment-resistant or intractable epilepsy. For reasons largely unknown, seizures in this subset of children persist long past their discovery in early childhood despite being treated with multiple medications and undergoing surgery to remove the affected parts of their brain. Diagnosed with epilepsy at age 5, life for Dameral has always come with seizures attached. When his seizures returned after a second brain surgery shortly after his 16th birthday, his mom Linley Allen, hoped for a medical breakthrough. “We needed to find something else since another surgery was out of the question,” Allen said. “We had heard about a drug being studied for a more severe seizure condition. I kept holding onto hope that it might be expanded to treat Shanny’s type of seizures because it was all we had at the time.”   See all and the original News article here: New Drug Trial Gives Hope for Treatment-Resistant Epilepsy